Recent Updates
Recently added Catalysts
TLPH Positive Sentiment

Talphera to Report Second Quarter 2026 Financial Results on Wednesday, August 12, 2026

Key Takeaway: Talphera, Inc. will hold a conference call on August 12, 2026, to discuss its second quarter financial results and recent business developments. The call will take place at 4:30 PM ET. Talphera is known for its innovative therapies, with its lead candidate, Niyad, currently under investigation as an anticoagulant. The company has received FDA Breakthrough Device Designation for nafamostat.

Market Sentiment Analysis

POSITIVE FACTORS

  • Talphera is focused on innovative therapies for medically supervised settings.
  • The company has a lead product candidate, Niyad, under investigation.
  • Nafamostat has received Breakthrough Device Designation from the FDA.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+222%
120-day peak, hindsight
Typical move
22.4%
average across 2 past catalysts
Cash runway
~16 mo
Low dilution risk
Lead asset
sufentanil
Phase 3 · Moderate-to-severe Acute Pain

Full Press Release Details

SAN MATEO, Calif., Aug. 5, 2026 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will host a conference call and webcast on Wednesday, August 12, 2026 at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss financial results for the second quarter ended June 30, 2026 and recent business progress.

Conference Call and Webcast Information

• Date: Wednesday, August 12, 2026 at 4:30 PM ET/1:30 PM PT
• Participant Dial-in (North America): 1-800-836-8184
• Participant Dial-in (International): 1-646-357-8785
• Conference ID: 50873
• Webcast Access: Click here
The event can also be accessed in the Upcoming Events page in the Investors section of the Talphera website at www.talphera.com.
A replay of the webcast will be available on the Talphera website for 90 days after the event.

About Talphera, Inc.

Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. Talphera's lead product candidate, Niyad ® is a lyophilized formulation of nafamostat and is currently being studied under an investigational device exemption (IDE) as an anticoagulant for the extracorporeal circuit. Nafamostat has received Breakthrough Device Designation status from the U.S. Food and Drug Administration (FDA).
This release is intended for investors only. For additional information about Talphera, please visit www.talphera.com.

Frequently Asked Questions

When will Talphera report its Q2 2026 financial results?

Talphera will report its Q2 2026 financial results on August 12, 2026.

What is the purpose of the upcoming conference call?

The conference call will discuss Talphera's Q2 financial results and recent business progress.

How can I access the conference call?

You can access the conference call via dial-in or webcast on Talphera's website.

What is Talphera's lead product candidate?

Talphera's lead product candidate is Niyad, a formulation of nafamostat.

What designation has nafamostat received from the FDA?

Nafamostat has received Breakthrough Device Designation from the FDA.

Last updated: Aug 5, 2026